Avulux has received De Novo marketing authorisation from the FDA, establishing the first recognised device classification for ...
Erasca has been granted Fast Track Designation by the FDA for ERAS‑0015, an oral pan‑RAS molecular glue being developed for ...
AC Immune has announced encouraging preliminary findings from its phase 1 first‑in‑human study of ACI‑19764, an orally ...
FairJourney Bio has published a peer‑reviewed study in mAbs describing a novel antibody‑engineering approach designed to ...
VarmX has enrolled the first participant in its global phase 3 EquilibriX S trial evaluating VMX C001 for the rapid ...
Teva Pharmaceuticals has announced that the US Food and Drug Administration has accepted the new drug application for ...
Lundbeck has secured orphan designation from the European Commission for asedebart, its investigational anti‑ACTH monoclonal ...
The MHRA’s position is that MBMPs fall within the scope of the existing UK medicines regulatory framework set out in the ...
Unlike antibody drug conjugates, KJ‑103 does not contain a cytotoxic payload. It recruits immune cells to kill tumour cells ...
HUTCHMED has reported positive high‑level results from the Saffron phase 3 trial evaluating Orpathys (savolitinib) plus ...
VarmX has enrolled the first participant in its global phase 3 EquilibriX S trial evaluating VMX C001 for restoring normal coagulation in patients taking FXa inhibitors who require an urgent surgery ...
Androlabs has appointed EffRx Pharmaceuticals as its commercial partner in Switzerland for Testavan, a testosterone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results